EMEA-002514-PIP01-18
Key facts
| Active substance |
|
| Therapeutic area |
Oto-rhino-laryngology
|
| Decision number |
P/0170/2019
|
| PIP number |
EMEA-002514-PIP01-18
|
| Pharmaceutical form(s) |
Nasal spray, suspension
|
| Condition(s) / indication(s) |
Treatment of allergic rhinitis / rhino-conjunctivitis
|
| Route(s) of administration |
Intranasal use
|
| Contact for public enquiries |
Glenmark Pharmaceuticals Europe Ltd
Tel.: +44 1923202950 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-002514-PIP01-18
|
| Compliance opinion date |
27/03/2020
|
| Compliance outcome |
positive
|